Upregulation of the B7/CD28 family member B7-H3 in bladder cancer

DEYAO WU, ZICHUN ZHANG, HUIXING PAN, YUANFENG FAN, PING QU and JIAN ZHOU

Department of Urology, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China

Received February 19, 2014; Accepted November 27, 2014

DOI: 10.3892/ol.2014.2828

Abstract. Dysregulation of B7-H3 has been observed in a variety of types of human cancers. In the present study, the mRNA expression level of B7-H3 was analyzed in bladder cancer by performing semi-quantitative reverse transcription-polymerase chain reaction on clinical specimens from transitional cell carcinomas (TCCs) and their normal adjacent tissues (NATs). Immunohistochemical analysis was performed to compare the protein expression level of B7-H3 in TCCs and the paired NATs. The present study indicated that the B7-H3 mRNA expression level was significantly higher in the TCC samples compared with the paired NAT samples. Furthermore, immunohistochemical analyses indicated that the B7-H3 protein expression level was significantly upregulated in the TCC samples compared with in the paired NAT samples, indicating that B7-H3 dysregulation may be important in the progression of bladder cancer.

Introduction

Bladder cancer is one of the most common malignancies worldwide. In males, bladder cancer is the fourth and seventh most common malignancy in the United States and the Western world, respectively, behind lung, prostate, colon, stomach, liver and esophageal cancers. Furthermore, bladder cancer is the second most common cause of mortality among genitourinary tumors, with ~72,570 new cases and 15,210 deaths occurring in males and females in 2013 (1-3). Transitional cell carcinoma (TCC) accounts for ~90% of cases of bladder cancer, whereas squamous cell carcinoma accounts for ~5% and adenocarcinomas ~1-2% of cases (4). At presentation, ~70% of cases of bladder cancer are non-muscle invasive (stages Tis, Ta and T1) which is typically low grade, multifocal, superficial and papillary, and 30% are muscle invasive (stages T2, T3 and T4), according to the TNM staging system (3). Numerous studies investigating the etiology of bladder cancer have been conducted; however, current understanding of the cellular and molecular mechanisms that underlie the processes of bladder cancer carcinogenesis and progression is poor.

The most common treatment for bladder cancer patients is endoscopic resection (5,6). Patients exhibiting non-invasive, low-grade bladder cancer typically undergo a treatment strategy of simple resection and fulguration of the tumor, followed by selective use of intravesical chemotherapy (7). Patients exhibiting the more aggressive muscle-invasive form of bladder cancer are usually treated with radical cystectomy (8). Therefore, bladder cancer patients require monitoring for cancer recurrence or progression. Furthermore, it is important to predict the prognosis of bladder cancer patients to enable the implementation of the most effective treatment strategy for prolonged survival.

Co-stimulation and -inhibition of T-cells is primarily generated by interactions between B7 immune regulatory ligands and cluster of differentiation (CD)28 receptors (9). Identification of new members of the B7/CD28 families has expanded the B7 family to include: B7h (CD275), B7x (B7-H4 or B7S1), B7-H3 (CD276), B7-1 (CD80), B7-2 (CD86), PD-L1 (CD274) and PD-L2 (CD273) (10). Phylogenetically, the B7 family is divided into three groups (11): Group I (B7-1, B7-2, and B7h) is involved in low-stage T-cell responses, as well as T- and B-cell interactions in lymphoid tissues (12); group II (PD-L1 and PD-L2) is involved in peripheral immune tolerance and T-cell impairment during chronic viral infections (13,14); and group III [B7-H3 (B7RP-2) and B7x (B7-H4, B7S1)], which contains the most recently identified members of the B7 family, is considered to attenuate peripheral immune responses via co-inhibition (9). The counter-receptors and precise roles of B7 proteins in T-cell regulation are yet to be defined; however, it is proposed that they are significant factors in the interaction between tumors and the immune system.

To the best of our knowledge, B7-H3 expression in bladder cancer has not yet been examined. Thus, the present study examines the mRNA and protein expression levels of B7-H3 in bladder cancer by performing semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical analysis, respectively, of clinical specimens.
from TCC samples and their normal adjacent tissues (NATs). The mRNA and protein expression levels of B7-H3 were significantly upregulated in the TCC samples compared with the paired NAT samples.

Materials and methods

Patients and clinical specimens. Seventeen tissue specimens were collected from bladder cancer patients of the Yancheng City No. 1 People's Hospital (Yancheng, China). Following receipt of written informed consent, tissues were obtained under a general tissue collection protocol approved by the Institutional Review Board of Yancheng City No. 1 People's Hospital. Tissues were immediately snap-frozen in liquid nitrogen.

RNA extraction and complementary (c)DNA synthesis. Total RNA was extracted from the tissue samples using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and treated with RNase-free DNase (Sangon Biotech Co., Ltd., Shanghai, China) to remove genomic DNA contamination, according to the manufacturer's instructions. The integrity and yield of RNA was quantified spectrophotometrically (UV-1601; Shimadzu Corporation, Kyoto, Japan) by measuring the absorbance at 260 nm (A260) and 280 nm (A280) to determine the A260/A280 ratio of pure RNA as ~1.8. RNA was stored at -80°C for subsequent analysis and cDNA synthesis was performed using the ReverTra Ace qPCR RT Kit (Toyobo Biotech, Shanghai, China) to remove genomic DNA contamination. Total RNA was isolated and complementary (c)DNA synthesis was performed using the ReverTra Ace qPCR RT Kit (Toyobo Biotech Co., Ltd., Shanghai, China) to remove genomic DNA contamination. The primer sequences for PCR were as follows: Forward, 5'-GCAGAAGGGGCGGAGATGA-3' for the forward, 5'-ATTCAACGGCACAGTCAAGG-3' and reverse, 5'-GTGACCAGCACATGCTTCCGTG-3' for B7-H3; and forward, 5'-CAGGGCAGCCTATGACATTCCC-3' and reverse, 5'-GCAGAAGGGGCGGAGATGA-3' for the internal control. The following PCR cycling parameters were employed: 95°C for 5 min, followed by 42 cycles of 95°C for 5 sec, 60°C for 1 min and 72°C for 1 min, and then 72°C for 7 min. Equal volumes of the PCR reaction were subjected to electrophoresis on 2% agarose gels and PCR fragments were visualized by ethidium bromide staining. Images were captured on a gel documentation system and analyzed using an AlphaImager® 2200 (Alpha Innotech Co., San Leandro, CA, USA).

Semi-quantitative RT-PCR. Total RNA was isolated and analyzed for B7-H3 expression by semi-quantitative RT-PCR. The primer sequences for PCR were as follows: Forward, 5'-CAGGGCAGCCTATGACATTCCC-3' and reverse, 5'-GTGACCAGCACATGCTTCCGTG-3' for B7-H3; and forward, 5'-ATTCAACGGCACAGTCAAGG-3' and reverse, 5'-CAGGGCAGCCTATGACATTCCC-3' for the GAPDH internal control. The following PCR cycling parameters were employed: 95°C for 5 min, followed by 42 cycles of 95°C for 45 sec, 56°C for 1 min and 72°C for 1 min, and then 72°C for 7 min. Equal volumes of the PCR reaction were subjected to electrophoresis on 2% agarose gels and PCR fragments were visualized by ethidium bromide staining. Images were captured on a gel documentation system and analyzed using an AlphaImager® 2200 (Alpha Innotech Co., San Leandro, CA, USA).

Immunohistochemical staining. At room temperature, the tissue samples were fixed in 4% 3-paraformaldehyde in phosphate buffered saline (PBS) for 24 h, embedded in paraffin, cut into sections (width, 5 µm) and mounted onto poly-L-lysine-coated slides. Initially, the slides were heated to 56°C in an oven for 2 h. Following dewaxing in xylene and rehydration in gradient alcohols, the slides were heated to boiling in 10 mmol/l sodium citrate buffer (pH 6.8) for 10 min using a microwave. Following inactivation of endogenous peroxidase activity with 3% hydrogen peroxide in methanol treatment, the samples were blocked using blocking solution (5% goat serum in PBS) for 20 min and incubated with primary mouse anti-human monoclonal B7-H3 antibodies (1:1,000; cat. no. BC062581; Bioworld Technology, Inc., St. Louis Park, MN, USA) overnight at 4°C. Following incubation, secondary biotinylated goat anti-mouse antibodies (1:1,000; cat. no. BS10004; Bioworld Technology, Inc.) and ABC reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) were applied sequentially and according to the manufacturer's instructions. The slides were counterstained with hematoxylin, briefly washed with 30 mmol/l ammonium hydroxide and mounted with permanent mounting medium. Each experiment was performed in triplicate and conducted under identical conditions.

To quantify the immunostaining intensity, the integrated optical density (IOD) was calculated. Digitally fixed images were analyzed at a magnification of x400 using an Axio-Imager A1 light microscope (Carl Zeiss AG, Oberkochen, Germany) equipped with Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA). For each sample, the IOD was calculated for the same sized arbitrary area. All data are presented as a mean value and statistical analysis was conducted to compare the results of the various experimental groups.

Statistical methods. Data are presented as the mean ± standard deviation, and compared using a Student's t-test in Stata software (version 8.2; StataCorp LP, College Station,
Results

mRNA expression level of B7-H3 in TCC and NAT samples. The relative mRNA expression levels of B7-H3 in 17 TCC and the paired NAT samples were examined using semi-quantitative RT-PCR. In individual patients (Fig. 1A) and as a mean value (Fig. 1B), B7-H3 mRNA expression levels were significantly higher in TCC samples compared with the paired NAT samples (P<0.05).

Protein expression level of B7-H3 in TCC and NAT samples. The protein level of B7-H3 in TCCs and NATs was compared using immunohistochemistry (Fig. 2A). For quantitative analysis of immunostaining intensity, the IOD was calculated using Image-Pro Plus 6.0 software (Media Cybernetics; Fig. 2B). The results indicated that the B7-H3 protein level was significantly upregulated in the TCC samples compared with the paired NAT samples (P<0.05).

Association between B7-H3 mRNA expression level, and the tumor stage and grade of TCC patients. Previous studies have demonstrated that the expression of B7-H3 is associated with
aggressive behavior in prostate cancer and clear cell renal cell carcinoma (15,16). Therefore, the present study investigated whether the mRNA expression level of B7-H3 is associated with the tumor stage and grade in bladder cancer patients. Statistical analysis indicated no significant association between the B7-H3 mRNA expression level, and the tumor stage (Fig. 3A) and grade (Fig. 3B).

**Discussion**

In the present study, the mRNA and protein expression levels of B7-H3 were evaluated in TCC samples. In a significant fraction of bladder cancer patients, the mRNA and protein expression levels of B7-H3 were upregulated. To the best of our knowledge, this is the first report demonstrating alterations in the expression of B7-H3 in TCC.

Human B7-H3 is a member of the B7 family and shares 20-27% amino acid identity with other B7 proteins (17). B7-H3 exists in two forms which appear to be functionally identical; mouse B7-H3 contains extracellular IgV-IgC domains, whereas tandemly duplicated (IgV-IgC) domains are present in human B7-H3 due to exon duplication (18). B7-H3 was initially detected in interferon-γ (IFN-γ)-treated dendritic cells, and has since been identified to be inducible in monocytes, T cells, B cells and natural killer cells (19). Detailed analysis of the expression of B7-H3 in various tissues has revealed its immunobiological significance. At the transcriptional level, B7-H3 is expressed in the majority of organs (17,20), however, at the protein level, B7-H3 is expressed in human breast, bladder, liver, lung, lymphoid organs, placenta, prostate and testis (10). Furthermore, B7-H3 has been observed to be upregulated in prostate cancer (15), non-small cell lung cancer (21), gastric (22) and ovarian cancer (23). However, the specific cell type of B7-H3-positive cells in each of these organs has yet to be determined. The differential mRNA and protein expression patterns indicate that B7-H3 is post-transcriptionally regulated, although, the molecular mechanisms regulating B7-H3 expression remain unclear.

At present, there is no consensus regarding the physiologic or pathophysiologic roles of B7-H3, as immune stimulatory and inhibitory effects have been described for this ligand (24). The study that initially identified human B7-H3 demonstrated that it exhibits a co-stimulatory effect on T-cells (20) and a co-inhibitor in TCC. Although the present study identified that B7-H3 expression levels were higher in invasive and high grade TCCs, compared with non-invasive and low grade TCCs, the association of B7-H3 expression with these clinicopathological features was not statistically significant. The small sample size (n=17) may have contributed to the lack of significant results. Thus, further studies with larger sample sizes are required to clarify the present data.

In addition, further investigations are required to determine an arbitrary cutoff value for B7-H3 expression levels in the prognosis of bladder, to improve its clinical significance. In addition, further investigation may explain the mechanisms of B7-H3 upregulation and reveal a novel predictor of human bladder cancer.

In conclusion, our data demonstrate that B7-H3 is significantly upregulated in TCC samples compared with the paired NAT samples, indicating that higher expression of B7-H3 may be important during the progression of bladder cancer.

**References**

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573, 2010.
3. Kirkali Z, Chan T, Manoharan M, et al: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (Suppl 1): 4-34, 2005.
4. WU D, Tao J, Ding J, et al: Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. Mol Med Rep 7: 684-688, 2013.
5. Hirata H, Ueno K, Shahryari V, et al: Oncogenic miRNA-182-5p targets Smaad4 and RECK in human bladder cancer. PloS One 7: e5056, 2012.
6. Pasin E, Josephson DY, Mitra AP, et al: Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10: 31-43, 2008.
7. Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186-2190, 2004.
8. Said N, Sanchez-Carbano M, Smith SC and Theodorescu D: RhoGD2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest 122: 1503-1518, 2012.
9. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 23: 1104-1112, 2010.
10. Hofmeyer KA, Ray A and Zang X: The contrasting role of B7-H3. Mod Pathol 23: 1104-1112, 2010.
11. Zang X, Loke P, Kim J, Murphy K, Waitz R and Allison JP: B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Nat Acad Sci USA 106: 10388-10392, 2003.
12. Zang X, Loke P, Kim J, Murphy K, Waitz R and Allison JP: B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Nat Acad Sci USA 104: 19458-19463, 2007.
13. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung cancer 53: 143-151, 2006.
14. Arigami T, Uenosono Y, Hirata M, Yanagita S, Ishigami S and Natsugoe S: B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci 102: 1019-1024, 2011.
15. Fauci JM, Straughn JM Jr, Ferrone S and Buchsbaum DJ: A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol 127: 420-425, 2012.
16. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007.
17. Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 173: 5445-5450, 2004.
18. Wang L, Fraser CC, Kikly K, Wells A, Ban H, Coyle AJ, Chen L and Hancock WW: B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 35: 428-438, 2005.
19. Luo L, Qiao H,Meng F, Dong X, Zhou B, Jiang H, Kanwar JR, Krissansen GW and Sun X: Arsenic trioxide synergizes with B7-H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int J Cancer 118: 1823-1830, 2006.
20. Lupu CM, Eisenbach C, Kuefner MA, Schmidt J, Lupu AD, Strommel W and Encke J: An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 10: 635-645, 2006.
21. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Pytte S, Elia A, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4: 899-906, 2003.
22. Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y and Dong C: Murine B7-H3 is a negative regulator of T cells. J Immunol 173: 2500-2506, 2004.